Boehringer Ingelheim to debut signature products at CIIE
The logo of German pharmaceutical company Boehringer Ingelheim is seen at its building in Shanghai, February 1, 2019. [Photo/Agencies]
German biopharmaceutical company Boehringer Ingelheim will hold global and Asian debuts for signature products among other innovative solutions during the fourth China International Import Expo, a move signifying the "long-term commitment to China", according to a senior company executive.
The first innovative vial for the mixing of swine vaccines in animal health in China will be on display during the fair, making its premier appearance globally.
Besides, the world's first animal health stem cell product, a ready-to-use solution for the treatment of equine lameness, will make its Asian debut at the upcoming CIIE.
A three-time participant to the event, Boehringer Ingelheim's decision reflects its priority and commitment in the Chinese market, said Felix Gutsche, president and CEO of Boehringer Ingelheim China.
"I do think the CIIE continues to be a great stage to get into implementable concepts and drive them into implementation," he told China Daily.
The company sees itself as a witness and beneficiary of the event's spill-over effect. For instance, its Total Stroke Solutions has evolved from a conceptual prototype showcased at the inaugural CIIE into the current set of total solutions covering seven modules.
"Overall the CIIE has very positive effect on the visibility of our clinical programs," Gutsche said. "We've got a lot of attention and feedbacks from various provincial governments and city governments."
In the newly-established biopharma special zone, Boehringer Ingelheim will also present a "one-stop" biopharma contract development and manufacturing organization services, a common way to outsource drug development and manufacturing. This year, the company's CDMO base in Shanghai has tripled capacity from its initial size in 2017.
The company will also announce a new investment plan during the upcoming CIIE.
